| Literature DB >> 22436174 |
Mwai H Makoka1, William C Miller, Irving F Hoffman, Rushina Cholera, Peter H Gilligan, Debbie Kamwendo, Gabriel Malunga, George Joaki, Francis Martinson, Mina C Hosseinipour.
Abstract
BACKGROUND: Life-threatening infections present major challenges for health systems in Malawi and the developing world because routine microbiologic culture and sensitivity testing are not performed due to lack of capacity. Use of empirical antimicrobial therapy without regular microbiologic surveillance is unable to provide adequate treatment in the face of emerging antimicrobial resistance. This study was conducted to determine antimicrobial susceptibility patterns in order to inform treatment choices and generate hospital-wide baseline data.Entities:
Mesh:
Substances:
Year: 2012 PMID: 22436174 PMCID: PMC3342226 DOI: 10.1186/1471-2334-12-67
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
Characteristics of Study Population (N = 2056)
| Service | Syndrome | Total N (%)* | Male N(%) | Female N(%) | Age Mean ± SD |
|---|---|---|---|---|---|
| Overall | 2056 | 848 (43.3) | 1110 (56.7) | 26.0 ± 16.7 | |
| Paediatrics | 543 | 254 | 218 | 4.4 ± 4.9 | |
| Febrile child | 391 (89.5) | 192 (90.6) | 166 (87.8) | ||
| Neonates | 46 (10.5) | 20 (9.4) | 23 (12.2) | ||
| Medicine | 1213 | 506 | 692 | 34.8 ± 12.0 | |
| (adults) | Meningitis | 294 (25.1) | 133 (27.4) | 157 (23.3) | |
| Pneumonia | 360 (30.7) | 116 (23.9) | 240 (35.7) | ||
| Fever/sepsis | 518 (44.2) | 236 (48.7) | 276 (41.0) | ||
| Obs/Gyn | 127 | 0 | 127 | 24.7 ± 6.2 | |
| Meningitis | 9 (7.5) | 0 | 9 (7.5) | ||
| Pneumonia | 7 (5.8) | 0 | 7 (5.8) | ||
| Fever/sepsis | 14 (11.7) | 0 | 14 (11.7) | ||
| Prepartum sepsis | 8 (6.7) | 0 | 8 (6.7) | ||
| Puerperal sepsis | 46 (38.3) | 0 | 46 (38.3) | ||
| Gynaecological sepsis | 36 (30.0) | 0 | 36 (30.0) | ||
| Surgery | 166 | 89 | 73 | 21.6 ± 15.8 | |
| (adults and children) | Osteomyelitis | 9 (5.7) | 3 (3.6) | 5 (7.2) | |
| Necrotising fasciitis | 3 (1.9) | 2 (2.4) | 1 (1.5) | ||
| Abdominal Abscess | 84 (53.5) | 42 (50.6) | 40 (58.0) | ||
| Burn | 8 (5.1) | 3 (3.6) | 5 (7.2) | ||
| Septic arthritis | 53 (33.8) | 33 (39.8) | 18 (26.1) | ||
*Categories may not sum to the total because of missing data
Laboratory methods for identification and susceptibility testing
| Organism | Media | Tests for presumptive identification | Susceptibility panel | Method |
|---|---|---|---|---|
| BAP | Gram stain; | GNP | Disc diffusion | |
| MAC | TSI; | |||
| Indole; | ||||
| Colony morphology; | ||||
| Urease | ||||
| Enteric gram negative bacilli | BAP | Gram stain; | GNP | Disc diffusion |
| MAC | Colony morphology | |||
| Indole; | ||||
| Oxidase; | ||||
| TSI; | ||||
| Citrate; | ||||
| Urease | ||||
| BAP | Gram stain | None | None | |
| CHOC | Oxidase | |||
| TM | Thayer-Martin | |||
| BAP | Gram stain | GPP | Disc diffusion | |
| CHOC | Hemolysis Catalase | Oxacillin | ||
| Bile solubility | screening test | |||
| BAP | Gram stain | GPP | Disc diffusion | |
| CHOC | Catalase | Oxacillin | ||
| MSA | Coagulase | |||
| Staphlex | ||||
| Sabouraud's | Gram stain | None | None | |
| BAP | India Ink | |||
| Urease | ||||
| BAP | Gram stain | None | None | |
| CHOC | Oxidase | |||
| API-NH | ||||
| BAP | Haemolysis | GPP | Disc diffusion | |
| Gram stain | ||||
BAP = blood agar plate, MAC = MacConkey agar, CHOC = chocolate agar, TSI = triple-sugar with iron media, TM = Thayer-Martin agar, MSA = mannitol salt agar. Coagulase = tube coagulate test using human plasma; GPP = gram positive antibiotic panel, GNP = gram negative antibiotic panel, see Table 3.
Antibiotic resistant bacteria isolated from all specimens
| Gram positive organisms | ||||
|---|---|---|---|---|
| Antibiotic | Resistant n/N (%) | Resistant + Intermediate n/N (%) | Resistant n/N (%) | Resistant n/N (%) |
| Chloramphenicol | 59/171 (34.5) | 77/171 (45.0) | 30/95 (31.6) | 17/51 (33) |
| Clindamycin | 19/188 (10.1) | 72/188 (38.3) | 14/143 (9.8)† | 3/30 (10.0) † |
| Erythromycin | 62/220 (28.2) | 112/220 (50.9) | 51/122 (41.8) | 1/67 (1.5) |
| Gentamicin | 60/183 (32.8) | 77/183 (42.1) | 28/141 (19.9) | 23/27 (85.2) |
| Oxacillin | 70/230 (30.4) | 84/230 (36.5) | 46/147 (31.3) | 11/59 (18.6)* |
| Tetracycline | 135/222 (60.8) | 150/222 (67.6) | 81/129 (62.8) | 32/63 (50.8) |
| Tmp-Sxt | 149/199 (74.9) | 158/199 (79.4) | 88/127 (69.3) | 42/47 (89.4) |
| Resistant n/N (%) | Resistant + Intermediate n/N (%) | Resistant n/N (%) | Resistant + Intermediate n/N (%) | |
| Chloramphenicol | 49/69 (71.0) | 52/69 (75.4) | 12/17 (70.1) | 12/17 (70.6) |
| Gentamicin | 27/80 (33.8) | 31/80 (38.8) | 0/19 (0.0) | 2/19 (10.5) |
| Tmp-Sxt | 53/65 (81.5) | 54/65 (83.1) | 12/15 (80.0) | 12/15 (80.0) |
| Ampicillin | 65/84 (77.4) | 69/84 (82.1) | 18/21 (85.7) | 18/21 (85.7) |
| Ceftriaxone | 16/85 (18.8) | 29/85 (34.1) | 0/20 (5.0) | 1/20 (5.0) |
| Ciprofloxacin | 9/75 (12.0) | 20/75 (26.7) | 0/22 (0.0) | 0/22 (0.0) |
| Nalidixic acid | 26/79 (32.9) | 44/79 (55.7) | 0/20 (0.0) | 9/20 (45.0) |
Recovery of pathogens from clinical specimens†
| Specimen type | Positive (%) | No growth (%) | Contaminated (%) | Total |
|---|---|---|---|---|
| Blood | 241 (12.7) | 1479 (78.1) | 174 (9.2) | 1894 |
| Cerebrospinal fluid | 23 (15.2) | 128 (84.8) | 0 | 151 |
| Joint fluid | 13 (21.7) | 47 (78.3) | 0 | 60 |
| Pus | 86 (72.3) | 30 (25.2) | 3 (2.5)* | 119 |
| Bone | 7 (58.3) | 5 (41.7) | 0 | 12 |
†Repeat specimens were not done, and when an isolate was recovered from different specimens they were all counted. * Includes coagulase negative staphylococci and normal flora
Organisms recovered from different specimens
| Organism | Blood n (%) | CSF n (%) | Joint n (%) | Bone n (%) | Pus n (%) | Total n (%) |
|---|---|---|---|---|---|---|
| 92 (39.0) | 0 | 5 (38.5) | 3 (42.9) | 54 (62.8) | 154 (42.0) | |
| 56 (23.5) | 10 (43.5) | 3 (23.1) | 0 | 1 (1.2) | 70 (19.1) | |
| 20 (8.4) | 1 (4.4) | 2 (15.4) | 2 (28.6) | 11 (12.8) | 36 (9.8) | |
| 20 (8.4) | 1 (4.4) | 3 (23.1) | 0 | 0 | 24 (6.5) | |
| Gram negative bacilli* | 43 (18.5) | 2 (8.7) | 0 | 2 (28.6) | 20 (23.2) | 68 (18.5) |
| 2 (0.8) | 0 | 0 | 0 | 0 | 2 (0.5) | |
| 2 (0.8) | 9 (39.1) | 0 | 0 | 0 | 11 (3.0) | |
| Yeast/Candida | 2 (0.8) | 0 | 0 | 0 | 0 | 2 (0.5) |
| Total | 238 (100) | 23 (100) | 13 (100) | 7 (100) | 86 (100) | 367 (100) |
* includes E. coli, Klebsiella, Proteus, Pseudomonas, Citrobacter, Yersinia and Acinetobacter